Journal
VALUE IN HEALTH
Volume 22, Issue 6, Pages 661-668Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jval.2019.03.012
Keywords
cost-effectiveness analysis; drug pricing; reimbursement; specialty drugs
Funding
- AveXis Inc
Ask authors/readers for more resources
The concept of a reference case, first proposed by the US Panel on Cost-Effectiveness in Health and Medicine, has been used to specify the required methodological features of economic evaluations of healthcare interventions. In the case of gene therapy, there is a difference of opinion on whether a specific methodological reference case is required. The aim of this article was to provide a more detailed analysis of the characteristics of gene therapy and the extent to which these characteristics warrant modifications to the methods suggested in general reference cases for economic evaluation. We argue that a completely new reference case is not required, but propose a tailored checklist that can be used by analysts and decision makers to determine which aspects of economic evaluation should be considered further, given the unique nature of gene therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available